Vanucizumab - Roche

Drug Profile

Vanucizumab - Roche

Alternative Names: RG-7221; RO-5520985

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Angiopoietin-2 inhibitors; Immunomodulators; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Colorectal cancer

Most Recent Events

  • 12 Mar 2018 Roche completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, France, Belgium (IV) (NCT01688206)
  • 23 Oct 2017 Discontinued - Phase-II for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) in Spain, France, Belgium, Austria, Australia, USA (IV) (Roche pipeline, October 2017)
  • 08 Oct 2017 Adverse events and efficacy data from a phase I trial in Solid tumours released by Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top